Forsta AP Fonden Decreases Stock Holdings in HCA Healthcare, Inc. $HCA

Forsta AP Fonden cut its position in HCA Healthcare, Inc. (NYSE:HCA) by 0.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 54,400 shares of the company’s stock after selling 300 shares during the quarter. Forsta AP Fonden’s holdings in HCA Healthcare were worth $20,841,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of HCA. Brighton Jones LLC purchased a new stake in shares of HCA Healthcare during the 4th quarter valued at $1,021,000. Allworth Financial LP boosted its holdings in HCA Healthcare by 8.7% in the first quarter. Allworth Financial LP now owns 798 shares of the company’s stock worth $272,000 after acquiring an additional 64 shares in the last quarter. CWM LLC increased its holdings in shares of HCA Healthcare by 18.5% during the first quarter. CWM LLC now owns 12,395 shares of the company’s stock valued at $4,283,000 after acquiring an additional 1,931 shares in the last quarter. Signaturefd LLC grew its position in HCA Healthcare by 11.0% during the 1st quarter. Signaturefd LLC now owns 3,219 shares of the company’s stock worth $1,112,000 after purchasing an additional 319 shares during the last quarter. Finally, Dakota Wealth Management purchased a new position in shares of HCA Healthcare in the first quarter worth $221,000. Hedge funds and other institutional investors own 62.73% of the company’s stock.

HCA Healthcare Stock Performance

Shares of NYSE HCA opened at $474.08 on Thursday. The firm has a fifty day moving average of $431.29 and a 200 day moving average of $394.54. HCA Healthcare, Inc. has a one year low of $289.98 and a one year high of $479.43. The firm has a market cap of $108.18 billion, a PE ratio of 18.33, a PEG ratio of 1.38 and a beta of 1.41.

HCA Healthcare (NYSE:HCA) last released its quarterly earnings results on Friday, October 24th. The company reported $6.96 earnings per share for the quarter, topping the consensus estimate of $5.64 by $1.32. HCA Healthcare had a net margin of 8.53% and a negative return on equity of 792.25%. The firm had revenue of $19.16 billion during the quarter, compared to the consensus estimate of $18.55 billion. During the same quarter in the prior year, the firm earned $4.90 EPS. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. On average, equities analysts predict that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 29th. Shareholders of record on Monday, December 15th will be issued a $0.72 dividend. The ex-dividend date is Monday, December 15th. This represents a $2.88 dividend on an annualized basis and a yield of 0.6%. HCA Healthcare’s dividend payout ratio (DPR) is presently 11.13%.

Insiders Place Their Bets

In other news, EVP Michael R. Mcalevey sold 3,892 shares of the stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $473.79, for a total value of $1,843,990.68. Following the completion of the sale, the executive vice president directly owned 3,487 shares in the company, valued at $1,652,105.73. This represents a 52.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael S. Cuffe sold 3,836 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the sale, the executive vice president directly owned 31,503 shares of the company’s stock, valued at approximately $13,194,716.52. This represents a 10.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on HCA. Barclays lifted their price target on HCA Healthcare from $445.00 to $494.00 and gave the stock an “overweight” rating in a research report on Monday, October 27th. Truist Financial upped their target price on HCA Healthcare from $460.00 to $495.00 and gave the company a “buy” rating in a research report on Monday, October 27th. JPMorgan Chase & Co. lifted their price objective on shares of HCA Healthcare from $360.00 to $370.00 and gave the company a “neutral” rating in a research note on Monday, August 4th. Bank of America raised their target price on shares of HCA Healthcare from $430.00 to $470.00 and gave the stock a “neutral” rating in a report on Monday, October 27th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of HCA Healthcare in a research note on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, HCA Healthcare has an average rating of “Moderate Buy” and a consensus price target of $473.53.

HCA Healthcare Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.